Clinical management of thromboembolic events arising from complications of COVID-19: integrative review

Detalhes bibliográficos
Autor(a) principal: Bispo, Laura Dayane Gois
Data de Publicação: 2021
Outros Autores: Machado, Natan Martins, Paula, Caio Lopes Pinheiro de, Oliveira, Jussiely Cunha, Santos, Ingrid Melo, Pinheiro, Fernanda Gomes de Magalhães Soares
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/21052
Resumo: Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used.
id UNIFEI_be1629cabe5f4c8acd8869b7730466ab
oai_identifier_str oai:ojs.pkp.sfu.ca:article/21052
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Clinical management of thromboembolic events arising from complications of COVID-19: integrative reviewManejo clínico de eventos tromboembólicos derivados de complicaciones del COVID-19: revisión integrativaGerenciamento clínico de eventos tromboembólicos provenientes de complicações da COVID-19: revisão integrativaTromboembolismo venosoEmbolia pulmonarCOVID-19Gestión clínica.Venous thromboembolismPulmonary embolismCOVID-19Clinical management.Tromboembolia venosaEmbolia pulmonarCOVID-19Gerenciamento clínico.Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used.Objetivo: identificar cómo se produce el manejo clínico de los pacientes infectados por COVID-19 que presentan tromboembolismo pulmonar y / o tromboembolismo venoso. Método: Se trata de una revisión integradora, realizada mediante la búsqueda de artículos en las bases de datos BVS, LILACS, MEDLINE, CINAHL Y SCOPUS, con una delimitación temporal de noviembre de 2019 a marzo de 2021. Resultados: Se incluyeron 24 artículos. El diagnóstico se produce a través del dímero D y el fibrinógeno. Para la farmacoterapia se administra heparina de bajo peso molecular (HBPM), 30 mg / 12 h en 12 h para la anticoagulación profiláctica, dosis escalonadas de HBPM con enoxaparina, 0,5 mg / kg dos veces al día para la anticoagulación y rivoxabán 10 mg / día para el postratamiento. anticoagulación. Conclusión: El tratamiento clínico de la TEP y la TEV se produce a través del aumento del dímero D o del fibrinógeno, y la TEP se confirma mediante una angiografía pulmonar. Para la anticoagulación, se usa principalmente HBPM.Objetivo: identificar de que forma ocorre o gerenciamento clínico de pacientes infectados por COVID-19 que apresentam tromboembolismo pulmonar e/ou tromboembolismo venoso. Método: Trata-se de uma revisão integrativa, realizada através da busca de artigos nas bases de dados BVS, LILACS, MEDLINE, CINAHL E SCOPUS, com delimitação temporal de novembro de 2019 a março de 2021. Resultados: Foram incluídos 24 artigos.  O diagnóstico ocorre através do D-dímero e fibrinogênio. Para a terapia medicamentosa, administra-se a Heparina de baixo peso molecular (HBPM), sendo 30 mg/12h em 12h para a anticogulação profilática, doses escalonadas de HBPM com enoxaparina, 0,5 mg/kg duas vezes por dia para a anticoagulação terapêutica e rivoraxabana 10mg/dia para a anticoagulação pós alta. Conclusão: O gerenciamento clínico de TEP e TEV ocorre através do aumento do D-dímero ou do fibrinogênio, com o TEP confirmado através da angiografia pulmonar. Para a anticoagulação, utiliza-se a HBPM, maiormente.Research, Society and Development2021-10-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2105210.33448/rsd-v10i13.21052Research, Society and Development; Vol. 10 No. 13; e138101321052Research, Society and Development; Vol. 10 Núm. 13; e138101321052Research, Society and Development; v. 10 n. 13; e1381013210522525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/21052/18751Copyright (c) 2021 Laura Dayane Gois Bispo; Natan Martins Machado; Caio Lopes Pinheiro de Paula; Jussiely Cunha Oliveira; Ingrid Melo Santos; Fernanda Gomes de Magalhães Soares Pinheirohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBispo, Laura Dayane GoisMachado, Natan Martins Paula, Caio Lopes Pinheiro de Oliveira, Jussiely CunhaSantos, Ingrid MeloPinheiro, Fernanda Gomes de Magalhães Soares 2021-11-21T18:26:28Zoai:ojs.pkp.sfu.ca:article/21052Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:40:32.818723Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
Manejo clínico de eventos tromboembólicos derivados de complicaciones del COVID-19: revisión integrativa
Gerenciamento clínico de eventos tromboembólicos provenientes de complicações da COVID-19: revisão integrativa
title Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
spellingShingle Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
Bispo, Laura Dayane Gois
Tromboembolismo venoso
Embolia pulmonar
COVID-19
Gestión clínica.
Venous thromboembolism
Pulmonary embolism
COVID-19
Clinical management.
Tromboembolia venosa
Embolia pulmonar
COVID-19
Gerenciamento clínico.
title_short Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
title_full Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
title_fullStr Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
title_full_unstemmed Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
title_sort Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
author Bispo, Laura Dayane Gois
author_facet Bispo, Laura Dayane Gois
Machado, Natan Martins
Paula, Caio Lopes Pinheiro de
Oliveira, Jussiely Cunha
Santos, Ingrid Melo
Pinheiro, Fernanda Gomes de Magalhães Soares
author_role author
author2 Machado, Natan Martins
Paula, Caio Lopes Pinheiro de
Oliveira, Jussiely Cunha
Santos, Ingrid Melo
Pinheiro, Fernanda Gomes de Magalhães Soares
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Bispo, Laura Dayane Gois
Machado, Natan Martins
Paula, Caio Lopes Pinheiro de
Oliveira, Jussiely Cunha
Santos, Ingrid Melo
Pinheiro, Fernanda Gomes de Magalhães Soares
dc.subject.por.fl_str_mv Tromboembolismo venoso
Embolia pulmonar
COVID-19
Gestión clínica.
Venous thromboembolism
Pulmonary embolism
COVID-19
Clinical management.
Tromboembolia venosa
Embolia pulmonar
COVID-19
Gerenciamento clínico.
topic Tromboembolismo venoso
Embolia pulmonar
COVID-19
Gestión clínica.
Venous thromboembolism
Pulmonary embolism
COVID-19
Clinical management.
Tromboembolia venosa
Embolia pulmonar
COVID-19
Gerenciamento clínico.
description Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/21052
10.33448/rsd-v10i13.21052
url https://rsdjournal.org/index.php/rsd/article/view/21052
identifier_str_mv 10.33448/rsd-v10i13.21052
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/21052/18751
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 13; e138101321052
Research, Society and Development; Vol. 10 Núm. 13; e138101321052
Research, Society and Development; v. 10 n. 13; e138101321052
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052691437846528

Registros relacionados